Apixaban and Urokinase: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Aug 8, 2026 · Source data updated Jul 11, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Apixaban
Urokinase
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Apixaban (Eliquis) is a blood thinner. Urokinase is a clot-buster, given in a hospital to break up dangerous clots. Both of these make it harder for your blood to clot, so using them together can add up and raise your chance of bleeding. That can mean bruising, bleeding that is hard to stop, or bleeding you cannot see happening inside your body.
The good news is that this combination is usually only used in a hospital setting where your team watches you very closely. If you ever need both, your care team can manage this by monitoring you carefully. Please talk with your doctor or pharmacist before changing anything.
Effect: Additive increase in bleeding risk when apixaban (a direct factor Xa inhibitor anticoagulant) is combined with urokinase (a fibrinolytic/thrombolytic). Neither is a prodrug requiring activation; the interaction is pharmacodynamic (additive), not a metabolic/PK change.
Direction: Increased anticoagulant/hemostatic impairment, raising risk of major hemorrhage.
Evidence: Theoretical; severity major. Onset unspecified.
Management:
- Monitor for external and internal bleeding signs.
- Close clinical and lab monitoring, including appropriate coagulation/PT testing.
- Observe surgical wound drainage; check Hb periodically.
- Suspect bleeding if Hb falls or BP drops.
What happens
An increased risk of bleeding
Interaction Deep Dive
Because their effects are additive, taking an anticoagulant together with a fibrinolytic (eg, thrombolytic) agent can raise the likelihood of major bleeding events1. Safe coadministration has been shown in two studies, one involving low-dose therapy 4 and another using low-intensity warfarin (that is, an INR of 1.7 or below) alongside a thrombolytic agent 5. Nevertheless, when an anticoagulant must be given at the same time as a fibrinolytic agent, clinical monitoring for indications of internal or external bleeding is warranted in patients. Monitoring through laboratory testing is likewise recommended 2. Drainage from surgical wounds should be watched carefully. Bleeding should be suspected when Hb levels drop or blood pressure declines 3.
Why it happens (mechanism)
Additive effects
How to manage this interaction
This combination is generally reserved for the hospital, where your team can watch you closely. If both are needed, they will manage the added bleeding risk rather than leave it unmonitored.
- Keep taking medications exactly as prescribed; do not start or stop either on your own.
- Your team may run blood clotting tests and check your blood counts (hemoglobin).
- They will watch for bleeding, including at surgical or wound sites, and check your blood pressure.
Tell your care team right away about unusual bruising, bleeding that will not stop, black or bloody stools, pink or red urine, severe headache, or feeling faint.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
3 reports — tap to read
a) In clinical studies of patients undergoing percutaneous transluminal coronary angioplasty (PTCA) or percutaneous coronary intervention (PCI), giving bivalirudin together with thrombolytic agents, glycoprotein IIb/IIIa inhibitors, warfarin, or heparin was linked to a higher risk of major bleeding events compared with patients who did not receive these concurrent medications 1. Any agent capable of raising the risk of hemorrhage should be stopped before starting desirudin therapy 2.
b) A Finnish study assessing streptokinase together with oral anticoagulants for the treatment of DVT found that warfarin administration caused no problems, though lower doses were used during the streptokinase infusion. Forty-four patients were started on warfarin 0.5 mg and streptokinase 600,000 international units. Streptokinase 600,000 international units/hour was continued for 3 days, and phlebography was carried out to assess resolution of the thrombotic occlusion. Treatment was extended for another 3 days if lysis was not complete. When needed, warfarin was administered to maintain the protein phosphatase (PP) activity level between 0.1 and 0.2. Hemorrhage led to discontinuation of treatment in 8 of the 44 patients (18.2%). Even though this study records concurrent use of oral anticoagulants and streptokinase, both the anticoagulant and streptokinase were begun at the same time. Because 3 to 5 days are needed before hypoprothrombinemia develops, these patients did not experience the true interaction whereby the thrombolytic effect of streptokinase produces hypoprothrombinemia as a result of concurrent warfarin use 4.
c) In a study examining registry data from 45,074 patients who received IV tissue plasminogen activator for acute ischemic stroke, there was no significant rise in the risk of symptomatic intracerebral hemorrhage or death among patients on warfarin therapy with an INR of 1.7 or less (n=768) compared with patients not treated with warfarin (n=43,651), after adjustment for age, stroke severity, and comorbidities 5.
Common questions
Can I take Apixaban and Urokinase together?
Combining apixaban with urokinase adds up to a higher risk of serious bleeding, so it is typically only done in a monitored hospital setting. Report any unusual bleeding to your care team and never change your medications on your own. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Apixaban and Urokinase interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Apixaban and Urokinase interaction managed?
This combination is generally reserved for the hospital, where your team can watch you closely. If both are needed, they will manage the added bleeding risk rather than leave it unmonitored. Keep taking medications exactly as prescribed; do not start or stop either on your own. Your team may run blood clotting tests and check your blood counts (hemoglobin). They will watch for bleeding, including… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
From our Q&A
Real reader questions about these medications, each personally answered by our pharmacist:
Questions for your pharmacist
- Does my dose of Apixaban or Urokinase need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (5)
- Product Information: ANGIOMAX(R) IV injection, bivalirudin IV injection. The Medicines Company, Parsippany, NJ, 2005.
- Product Information: Iprivask(TM), desirudin for injection. Aventis Pharmaceuticals Inc. Bridgewater, NJ, 2003.
- Product Information: Xarelto(R) oral film-coated tablets, rivaroxaban oral film-coated tablets. Bayer HealthCare (per manufacturer), Leverkusen, Germany, 2008. DailyMed
- Jarvinen P, Aromaa U, Roiha M, et al: Streptokinase and concomitant oral anticoagulants in the treatment of deep venous thrombosis. Klin Wochenschr 1978; 56:801-804. PubMed
- Mazya MV, Lees KR, Markus R, et al: Safety of intravenous thrombolysis for ischemic stroke in patients treated with warfarin. Ann Neurol 2013; 74(2):266-274. DOI
Keep reading about Apixaban
Keep reading about Urokinase
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist